Cirillo A, Marinelli D, Romeo U, Messineo D, et al. Correction: Pembrolizumab-based first-line treatment for PD-L1-positive,
recurrent or metastatic head and neck squamous cell carcinoma: a retrospective
analysis. BMC Cancer 2024;24:487.
PMID: 38632499